ReviewClinical journal of gastroenterology2016
Recent trends and future directions for the medical treatment of ulcerative colitis.
Review in Clinical journal of gastroenterology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 29 citations in OpenAlex.
- Effects of Spirulina supplementation in patients with ulcerative colitis: a double-blind, placebo-controlled randomized trial.BMC complementary medicine and therapies · 2024Trial
- Indigo naturalis is effective even in treatment-refractory patients with ulcerative colitis: a post hoc analysis from the INDIGO study.Journal of gastroenterology · 2020Trial
- Diagnostic accuracy of endoscopic findings for cytomegalovirus reactivation in hospitalized patients with ulcerative colitis.PloS one · 2026Article
- Clinical, pharmacology and in vivo studies of QingDai (indigo naturalis) promotes mucosal healing and symptom improvement in ulcerative colitis by regulating the AHR-Th17/Treg pathway.Journal of inflammation (London, England) · 2024Article
- Real-world efficacy and safety of advanced therapies in hospitalized patients with ulcerative colitis.Journal of gastroenterology · 2023Observational
- Analysis of the initial dose and reduction rate of corticosteroid for ulcerative colitis in clinical practice.JGH open : an open access journal of gastroenterology and hepatology · 2022Article
- Mass Spectrometric Behavior and Molecular Mechanisms of Fermented Deoxyanthocyanidins to Alleviate Ulcerative Colitis Based on Network Pharmacology.International journal of analytical chemistry · 2022Article
- Potential benefits of immunomodulator use with vedolizumab for maintenance of remission in ulcerative colitis.Journal of gastroenterology and hepatology · 2022Article
- Root Extract ofFrontiers in pharmacology · 2021Article
- Solving the questions regarding 5-aminosalitylate formulation in the treatment of ulcerative colitis.Journal of gastroenterology · 2020Review
- Efficacy and Safety ofFrontiers in pharmacology · 2020Review
- Integrating Pharmacology and Microbial Network Analysis with Experimental Validation to Reveal the Mechanism of Composite Sophora Colon-Soluble Capsule against Ulcerative Colitis.Evidence-based complementary and alternative medicine : eCAM · 2020Article
- Ulcerative Colitis: Shifting Sands.Drugs in R&D · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently, several medical treatments for ulcerative colitis (UC) have been developed, including 5-aminosalicylic acids (5-ASAs), corticosteroids, thiopurine, calcineurin inhibitors, and anti-tumor necrosis factor (TNF) α treatments. Treatment options including calcineurin inhibitors and anti-TNF treatment for refractory UC are discussed in this article. Furthermore, upcoming treatments are introduced, such as golimumab, vedolizumab, AJM300, tofacitinib. Budesonide foamwill be used as one treatment option in patients with distal colitis. Herbal medicine, such as Qing-Dai is also effective for active UC and may be useful for patients who are refractory to anti-TNFα treatments. In the near future, physicians will able to use many different treatments for UC patients. However, we should not forget 5-ASA and corticosteroids as the fundamental treatments for UC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.